Agenus announces late-breaking oral presentation at esmo-gi and strategies to advance botensilimab

Lexington, mass., may 24, 2022 (globe newswire) -- agenus inc. (nasdaq: agen), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate immune response to cancers and infections, today announced that its innate/adaptive immune activator, botensilimab, will be the subject of a late-breaking oral presentation at the upcoming esmo world congress on gastrointestinal cancer in barcelona, spain. in addition, agenus also announced broad efficiencies expected to reduce costs by 20% and drive botensilimab's accelerated development.
AGEN Ratings Summary
AGEN Quant Ranking